ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)
Lung Cancer
◽
10.1016/j.lungcan.2016.06.019
◽
2016
◽
Vol 99
◽
pp. 94-101
◽
Cited By ~ 7
Author(s):
Egbert F. Smit
◽
Yi-Long Wu
◽
Radj Gervais
◽
Caicun Zhou
◽
Enriqueta Felip
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Phase Iii
◽
Line Treatment
◽
Second Line
◽
Small Cell Lung
◽
Double Blind
◽
Phase Iii Study
Download Full-text
Related Documents
Cited By
References
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
Journal of Clinical Oncology
◽
10.1200/jco.2009.27.18s.cra8003
◽
2009
◽
Vol 27
(18S)
◽
pp. CRA8003-CRA8003
◽
Cited By ~ 7
Author(s):
R. S. Herbst
◽
Y. Sun
◽
S. Korfee
◽
P. Germonpré
◽
N. Saijo
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Phase Iii
◽
Line Treatment
◽
Second Line
◽
Small Cell Lung
◽
Double Blind
◽
Phase Iii Trial
Download Full-text
Faculty Opinions recommendation of EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.718505411.793498028
◽
2014
◽
Author(s):
Alexandru Grigorescu
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Phase Iii
◽
Line Treatment
◽
Second Line
◽
Small Cell Lung
◽
Phase Iii Study
Download Full-text
Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology
◽
10.1200/jco.2014.32.15_suppl.8046
◽
2014
◽
Vol 32
(15_suppl)
◽
pp. 8046-8046
◽
Cited By ~ 1
Author(s):
Egbert F. Smit
◽
Radj Gervais
◽
Caicun Zhou
◽
Enriqueta Felip
◽
Ji Feng Feng
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Phase Iii
◽
Second Line
◽
Efficacy And Safety
◽
Small Cell Lung
◽
Double Blind
◽
Phase Iii Study
Download Full-text
PS13 Late breaking Paclitaxel poliglumex vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): the STELLAR 2 phase III study
European Journal of Cancer Supplements
◽
10.1016/s1359-6349(05)82016-6
◽
2005
◽
Vol 3
(4)
◽
pp. 14
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Phase Iii
◽
Line Treatment
◽
Second Line
◽
Small Cell Lung
◽
Phase Iii Study
Download Full-text
A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer
BMC Cancer
◽
10.1186/1471-2407-10-633
◽
2010
◽
Vol 10
(1)
◽
Cited By ~ 22
Author(s):
Athanasios G Pallis
◽
Sophia Agelaki
◽
Athina Agelidou
◽
Ioannis Varthalitis
◽
Kostas Syrigos
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Single Agent
◽
Small Cell
◽
Phase Iii
◽
Line Treatment
◽
Second Line
◽
Small Cell Lung
◽
Phase Iii Study
Download Full-text
9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial
European Journal of Cancer Supplements
◽
10.1016/s1359-6349(09)71714-8
◽
2009
◽
Vol 7
(2)
◽
pp. 505
Author(s):
W.E.E. Eberhardt
◽
B.E. Johnson
◽
Y. Sun
◽
P. Germonpré
◽
N. Saijo
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Phase Iii
◽
Line Treatment
◽
Second Line
◽
Small Cell Lung
◽
Double Blind
◽
Phase Iii Trial
Download Full-text
O-099 XYOTAX™ vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): The STELLAR 2 phase III study
Lung Cancer
◽
10.1016/s0169-5002(05)80233-8
◽
2005
◽
Vol 49
◽
pp. S35
◽
Cited By ~ 10
Author(s):
P. Bonomi
◽
L. Paz-Ares
◽
C. Langer
◽
M. O'Brien
◽
R. Gervais
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Phase Iii
◽
Line Treatment
◽
Second Line
◽
Small Cell Lung
◽
Phase Iii Study
Download Full-text
REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.
Journal of Clinical Oncology
◽
10.1200/jco.2014.32.15_suppl.lba8006
◽
2014
◽
Vol 32
(15_suppl)
◽
pp. LBA8006-LBA8006
◽
Cited By ~ 2
Author(s):
Maurice Perol
◽
Tudor-Eliade Ciuleanu
◽
Oscar Arrieta
◽
Kumar Prabhash
◽
Konstantinos N. Syrigos
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Stage Iv
◽
Small Cell
◽
Phase Iii
◽
Line Treatment
◽
Second Line
◽
Small Cell Lung
◽
Double Blind
◽
Phase Iii Study
Download Full-text
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer
Annals of Oncology
◽
10.1093/annonc/mdu269
◽
2014
◽
Vol 25
(10)
◽
pp. 1941-1948
◽
Cited By ~ 13
Author(s):
J.V. Heymach
◽
S.J. Lockwood
◽
R.S. Herbst
◽
B.E. Johnson
◽
A.J. Ryan
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Phase Iii
◽
Line Treatment
◽
Second Line
◽
Small Cell Lung
◽
Phase Iii Study
Download Full-text
Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology
Annals of Oncology
◽
10.1093/annonc/mdv343.04
◽
2015
◽
Vol 26
◽
pp. vi74
◽
Cited By ~ 1
Author(s):
P. Bidoli
◽
F. Cappuzzo
◽
A. Favaretto
◽
O. Alabiso
◽
M. Tiseo
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Subgroup Analysis
◽
Stage Iv
◽
Small Cell
◽
Phase Iii
◽
Second Line
◽
Small Cell Lung
◽
Double Blind
◽
Phase Iii Study
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close